Your browser doesn't support javascript.
loading
A clinician's perspective on boron neutron capture therapy: promising advances, ongoing trials, and future outlook.
Shen, Shumin; Wang, Shanghu; Zhou, Dachen; Wu, Xiuwei; Gao, Mingzhu; Wu, Jinjin; Yang, Yucai; Pan, Xiaoxi; Wang, Nianfei.
Afiliación
  • Shen S; Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, China.
  • Wang S; Department of Radiotherapy, Anhui Chest Hospital, Hefei, China.
  • Zhou D; Department of General Surgery, The Second Hospital of Anhui Medical University, Hefei, China.
  • Wu X; Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, China.
  • Gao M; Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, China.
  • Wu J; Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, China.
  • Yang Y; Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, China.
  • Pan X; Department of Nuclear Medicine, The Second Hospital of Anhui Medical University, Hefei, China.
  • Wang N; Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, China.
Int J Radiat Biol ; 100(8): 1126-1142, 2024.
Article en En | MEDLINE | ID: mdl-38986056
ABSTRACT

PURPOSE:

This comprehensive review aims to provide a unique clinical perspective on the latest advances and ongoing boron neutron capture therapy (BNCT) trials for various cancers.

METHODS:

We critically analyzed clinical data from BNCT trials for head and neck cancer, glioblastoma, melanoma, meningioma, breast cancer, and liver tumors. We investigated differences in tumor responses and normal tissue toxicities among trials and discussed potential contributing factors. We also identified the limitations of early BNCT trials and proposed strategies to optimize future trial design.

RESULTS:

BNCT has shown promising results in treating head and neck cancer, with high response rates and improved survival in patients with recurrent disease. In glioblastoma, BNCT combined with surgery and chemotherapy has demonstrated survival benefits compared to standard treatments. BNCT has also been successfully used for recurrent high-grade meningiomas and shows potential for melanomas, extramammary Paget's disease, and liver tumors. However, differences in tumor responses and toxicities were observed among trials, potentially attributable to variations in treatment protocols, patient characteristics, and evaluation methods.

CONCLUSIONS:

BNCT is a promising targeted radiotherapy for various cancers. Further optimization and well-designed randomized controlled trials are needed to establish its efficacy and safety. Future studies should focus on standardizing treatment protocols and addressing limitations to guide clinical decision-making and research priorities.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Terapia por Captura de Neutrón de Boro Límite: Humans Idioma: En Revista: Int J Radiat Biol Asunto de la revista: RADIOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Terapia por Captura de Neutrón de Boro Límite: Humans Idioma: En Revista: Int J Radiat Biol Asunto de la revista: RADIOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido